Skip to content

Radiomic and Pathomic Study of Pituitary Adenoma Using Machine Learning

Machine Learning Modeling the Risk of Refractory Pituitary Adenoma Using Radiomic and Pathomic Data

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05108064
Enrollment
1000
Registered
2021-11-04
Start date
2019-01-01
Completion date
2024-12-31
Last updated
2022-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pituitary Neoplasms

Brief summary

Refractory pituitary adenoma is characterized by invasive tumor growth, continuous growth and/or hormone hypersecretion in spite of standardized multi-modal treatment such as surgeries, medications or radiations. Quality of life or even lives are threatened by these tumors. According to the 2017 World Health Organization's new classification guideline of pituitary adenoma, patients have to suffer from symptoms or complications caused by these tumors, to bear a heavy financial burden, and to accept additional therapeutic side effects when the diagnosis of refractory pituitary adenoma is made. If refractory pituitary adenoma could be predicted at early stage, these patients would be able to have a more frequent clinical follow-up, receive multiple effective treatment as early as possible, or even be enrolled in clinical trials of investigational medications, so as to prevent or delay the recurrence or persistent of the tumor growth. Therefore, the unmet clinical need falls into an early prediction system for refractory pituitary adenomas, which could provide accurate guidance for subsequent treatment in the early stage. The investigators have constructed a pituitary adenoma database including clinical data, radiological images, pathological images and genetic information. The investigators are proposing a study using machine learning to extract features from these multi-dimensional, multi-omics data, which could be further used to train a prediction model for the risk of refractory pituitary adenoma. The proposed model would also be validated in another prospectively collected database. The established model would be able to identify potential medication targets and provide guidance for personalized therapy of refractory pituitary adenoma.

Interventions

Results of artificial intelligence model will be compared with the gold standard

Sponsors

Huashan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients with pituitary adenoma

Exclusion criteria

* Patients who were not able to sign the informed consent

Design outcomes

Primary

MeasureTime frameDescription
The risk of refractory pituitary adenoma10 yearsPredicting the development of refractory pituitary adenoma after the first surgery

Secondary

MeasureTime frameDescription
Predicting Gamma Knife efficacy5 yearsPredicting endocrine remission after Gamma Knife surgery in Growth Hormone secreting pituitary adenoma
Predicting immunostainingTwo weeks after surgeryPredicting immunostaining in patients with non-functioning pituitary adenoma using H&E stained images
Predicting recurrence10 yearsPredicting relapse or regrowth of a non-functioning pituitary adenoma after the first surgery
Predicting endocrinopathy10 yearsPredicting endocrinopathy which warrant replacement after pituitary adenoma resection
Predicting surgical difficulty and complicationsTwo weeks after surgeryPredicting surgical difficulty and complications using pre-surgical radiomic features

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026